SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, ...
UNITY is on track to receive 24-week topline data from its Phase 2b ASPIRE study in diabetic macular edema this quarter, which could provide critical insights for future trials. UBX1325 (foselutoclax) ...
SAN FRANCISCO--(BUSINESS WIRE)--Unity (NYSE: U), the leading platform to create and grow games and interactive experiences, today announced financial results for the fourth quarter and fiscal year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results